PR84443

MENLO PARK, Calif., June 18, 2020 /PRNewswire=KYODO JBN/ --

IONpath, Inc. the leader in multiplexed spatial tissue imaging and analysis,

today announced the appointment of Brad Nelson to the position of Senior Vice

President of Marketing and Corporate Strategy. Mr. Nelson will lead marketing,

product management and application functions to meet the increasing demand for

translational medicine insights that can only be achieved with Multiplexed Ion

Beam Imaging (MIBI(TM)).

Logo - https://mma.prnewswire.com/media/1088947/IONpath_Logo.jpg

Rapid growth in immuno-oncology and adjacent markets requires approaches that

can sensitively detect and quantify the expression of multiple biomarkers while

preserving spatial information. IONpath is uniquely capable of addressing these

market needs and is positioned for rapid commercial growth both with their

MIBIScope(TM) instrument and their comprehensive Research Services offering.

Mr. Nelson will provide commercial leadership as IONpath meets this increasing

demand from pharma, biotech and academic customers.

"Brad brings a unique combination of broad marketing and corporate development

experience and a deep technical background," Dr. Harris Fienberg, IONpath CEO

said. "Our entire team is excited to have Brad on board to guide our

immuno-oncology strategy and expand our offerings into new markets."

Mr. Nelson has over twenty years of experience in leading rapid growth life

science and medical device organizations.  He has a track record of success at

early stage companies bringing new technology and applications to market,

driving rapid growth from product inception to broad scale adoption. Most

recently he served as Vice President of Marketing at Magnolia Medical

Technologies leading the brand and product portfolio development for the

company's Steripath technology which experienced rapid adoption and over 70

percent annual revenue growth.

Prior to Magnolia Medical, Mr. Nelson served as Head of Marketing and Director

of Corporate Development at Labcyte Inc., leading the development of new global

markets and collaborations that delivered sustained revenue growth and the

acquisition by Danaher Corporation. Previously he led the marketing

organization at Velocity11 Inc., building a highly differentiated brand and

robotics product portfolio that led to industry leading growth and the

acquisition by Agilent Technologies.

"I am thrilled to join the world class team at IONpath," Nelson said. "IONpath

has the rare combination of groundbreaking technology backed by a team of

scientists and engineers that can turn data into insights. Working closely with

our pharmaceutical, biotech and academic partners we will deliver on the

promise of precision medicine for oncology, immunology, neuroscience and

infectious disease markets enabling new discoveries that improve patient care."

About IONpath, Inc. and IONpath Research Services

IONpath, Inc. is revolutionizing tissue imaging to accelerate medical discovery

and improve human health. The company's MIBIscope(TM) System utilizes

Multiplexed Ion Beam Imaging (MIBI(TM)) technology, developed at Stanford

University, and represents a transformative step in tissue imaging by

simultaneously multiplexing up to 40 markers with specificity down to a single

cell. Leading research institutes, biotech and pharmaceutical companies are

using the MIBIscope in immuno-oncology, immunology and neuroscience research

where high-fidelity multiplexed imaging data is needed. In addition to the

MIBIscope(TM) System enhanced with MIBItracker(TM), IONpath empowers the

research and development initiatives of academic, biotech and pharmaceutical

partners through its comprehensive Research Services division.

Visit www.ionpath.com to learn more.

(c)2020 IONpath, Inc. All rights reserved. IONpath(R) is a registered trademark

and MIBI(TM) & MIBIscope(TM) are trademarks of IONpath, Inc. For Research Use

Only. Not for diagnostic use.

SOURCE  IONpath, Inc.

CONTACT: Terri Hnatyszyn, media@ionpath.com, (305) 803-0824